Robin Teskin focuses her practice on intellectual property law, with an emphasis on the biotechnology, pharmaceutical and chemical industries. Robin provides intellectual property advice to pharmaceutical, biotechnology, life sciences and medical device companies, research institutions, hospitals and universities throughout the world. Her practice includes patent prosecution, post-grant proceedings, licensing and transactional work with a focus on novel therapeutic treatments, biotechnology, polymers, genetics, diagnostics, biomarkers, nutraceuticals, probiotics, drug formulations and medical devices.
Ms. Teskin's more than 30 years of patent law experience involves all aspects of patent counseling and patent prosecution, including freedom-to-operate, due diligence, non-infringement, inventorship, invalidity, and Hatch-Waxman legal issues. Additionally, Ms. Teskin has experience in post-grant patent office proceedings including reissues, inter partes reviews (IPRs), post-grant reviews (PGRs), ex parte reexaminations and interferences.
Ms. Teskin's intellectual property experience spans a wide range of cutting-edge technologies including therapeutic antibodies, small molecules, polymer chemistry, vaccines, embryonic stem cells, transgenic animals, nuclear transfer, CRISPR, CAR-T cell and other cell therapies, transplantation, nucleic and protein detection methods, microfluidics, medical devices and automated diagnostic assays. She has substantial expertise in therapeutic antibodies, having managed the prosecution of a global patent portfolio covering the first therapeutic antibody approved by the FDA for use in treating human cancer. Ms. Teskin also has significant experience in overseeing patent portfolios relating to drugs which target checkpoint inhibitors. Further, Ms. Teskin has much experience counseling clients pursuing intellectual property relating to stem cell and nuclear transfer technologies, having managed the global portfolio of a major research university which procured the first patents directed to the nuclear transfer production of cloned animals and embryos, and further through her having managed the global patent portfolio of an emerging company pursuing intellectual property covering the manufacture of human cells derived from human embryonic stem cells for use in human cell therapies (e.g., the treatment of macular degeneration).
Prior to her admission to the bar, Ms. Teskin served as an assistant and primary patent examiner at the U.S. Patent and Trademark Office (USPTO), where she was among the first examiners selected to be part of the then-newly formed USPTO Biotechnology Group. While an examiner, she issued about 500 patents dealing with complex biotechnology research and was awarded a Bronze Medal for distinguished federal service.